This Tobacco Company is Required by FDA to Label Cigarettes “Helps People Smoke Less.”

0

INTERVIEW ON THE PRICE OF BUSINESS SHOW, MEDIA PARTNER OF THIS SITE.

Recently Kevin Price, Host of the nationally syndicated Price of Business Show, interviewed James Mish.

On a recent Price of Business show, Host Kevin Price interviewed James Mish, CEO of 22nd Century Group

According to the company, “With cigarette smoking and nicotine addiction ceaselessly causing health concerns in the U.S. and globally, 22nd Century Group, an innovative plant biotechnology company, has successfully developed a tobacco plant with significantly reduced levels of nicotine. The company’s new VLN cigarette, which is the only cigarette to have received modified risk tobacco product (MRTP)authorization from the FDA, is a combustible cigarette that contains 95% less nicotine than conventional cigarettes. With the FDA’s approval, it can make the claim: ‘Helps people smoke less.’

 

“The FDA and NIH spent more than $100 million on clinical studies and determined that this new tobacco plant technology reduces harm by breaking the addiction to nicotine. Their studies show that 22nd Century Group’s reduced nicotine cigarette not only helps people smoke less but also promotes more quit attempts.  The company recently announced its U.S. Pilot Market in Chicagoland Circle K as its first VLN® Retail Partner. The product will soon be on store shelves and into the hands of smokers who want to smoke less.  https://www.xxiicentury.com/ ”

 

 

“CEO James Mish has an outstanding track record of delivering profitable growth at both privately-held and publicly-traded science-driven companies with a focus on pharmaceutical and consumer products commercialization. Prior to joining 22nd Century, he served as President and CEO of Purisys, a synthetic cannabinoid API, ingredients and solutions provide to pharmaceutical and consumer products companies, and Noramco, a global leader in the production of controlled substances for the pharmaceutical industry.There, Mr. Mish led the private equity carve out of Noramco from Johnson & Johnson/Janssen Pharmaceuticals and spearheaded the subsequent creation and spinoff of Purisys from Noramco.”

LISTEN TO THE INTERVIEW IN ITS ENTIRETY HERE:

The Price of Business is one of the longest running shows of its kind in the country and is in markets coast to coast. The Host, Kevin Price, is a multi-award winning author, broadcast journalist, and syndicated columnist. Learn more about the show and its digital partners at www.PriceofBusiness.com (scroll down to the bottom of the page).

About Author

Leave a Reply

Your email address will not be published. Required fields are marked *

RSS
Follow by Email
YouTube
YouTube
LinkedIn
LinkedIn
Share